The neurokinin₁ receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

Bibliography

• ROILA F, HESKETH PJ, HERRSTEDT J: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann. Oncol. (2006) 17(1):20-28.
   PubMed Web of Science ®Google Scholar
• AAPRO MS, ALBERTS DS: Dexamethasone as an antiemetic in patients treated with cisplatin [letter]. N. Engl. J. Med. (1981) 305:520-520.
   PubMed Web of Science ®Google Scholar
• GRALLA RJ, ITRI LM, PISKO SE et al.: Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. (1981) 305:905-909.
   PubMed Web of Science ®Google Scholar
• KRIS MG, GRALLA RJ, CLARK RA, TYSON LB: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J. Natl. Cancer Inst. (1989) 81:42-46.
   PubMed Web of Science ®Google Scholar
• KRIS MG, RADFORD JE, PIZZO BA, INABINET R, HESKETH A, HESKETH PJ: Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J. Natl. Cancer Inst. (1997) 89:817-818.
   PubMed Web of Science ®Google Scholar
• POLI-BIGELLI S, RODRIGUES-PEREIRA J, CARIDES AD et al.: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer (2003) 97(12):3090-3098.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, GRUNBERG SM, GRALLA RJ et al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. (2003) 21(22):4112-4119.
   PubMed Web of Science ®Google Scholar
• KRIS MG, HESKETH PJ, HERRSTEDT J et al.: Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support. Care Cancer (2005) 13(2):85-96.
   PubMed Web of Science ®Google Scholar
• KRIS MG: Why do we need another antiemetic? Just ask. J. Clin. Oncol. (2003) 21(22):4077-4080.
   PubMed Web of Science ®Google Scholar
• Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N. Engl. J. Med. (2000) 342(21):1554-1559.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, KRIS MG, GRUNBERG SM et al.: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. (1997) 15(1):103-109.
   PubMed Web of Science ®Google Scholar
• GRUNBERG SM, DEUSON RR, MAVROS P et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 100(10):2261-2268.
   PubMed Web of Science ®Google Scholar
• GELING O, EICHLER HG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. (2005) 23(6):1289-1294.
   PubMed Web of Science ®Google Scholar
• LINDLEY C, GOODIN S, MCCUNE J et al.: Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am. J. Clin. Oncol. (2005) 28(3):270-276.
   PubMed Web of Science ®Google Scholar
• HICKOK JT, ROSCOE JA, MORROW GR et al.: 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. (2005) 6(10):765-772.
   PubMed Web of Science ®Google Scholar
• BOUNTRA C, BUNCE K, DALE T et al.: Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur. J. Pharmacol. (1993) 249(1):R3-R4.
   PubMed Web of Science ®Google Scholar
• GRALLA RJ, DE WIT R, HERRSTEDT J et al.: Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer (2005) 104(4):864-868.
   PubMed Web of Science ®Google Scholar
• PATEL L, LINDLEY C: Aprepitant – a novel NK1-receptor antagonist. Expert. Opin. Pharmacother. (2003) 4(12):2279-2296.
   PubMed Web of Science ®Google Scholar
• WARR DG, HESKETH PJ, GRALLA RJ et al.: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. (2005) 23(12):2822-2830.
   PubMed Web of Science ®Google Scholar
• MCCREA JB, MAJUMDAR AK, GOLDBERG MR et al.: Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin. Pharmacol. Ther. (2003) 74(1):17-24.
   PubMed Web of Science ®Google Scholar
• LINDLEY CM, HIRSCH JD, O’NEILL CV, TRANSAU MC, GILBERT CS, OSTERHAUS JT: Quality of life consequences of chemotherapy- induced emesis. Qual. Life. Res. (1992) 1:331-340.
   PubMedGoogle Scholar
• WARR DG, GRUNBERG SM, GRALLA RJ et al.: The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur. J. Cancer (2005) 41(9):1278-1285.
   PubMed Web of Science ®Google Scholar
• HERRSTEDT J, MUSS HB, WARR DG et al.: Efficacy and tolerability of aprepitant for the prevention of chemotherapy- induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer (2005) 104(7):1548-1555.
   PubMed Web of Science ®Google Scholar
• SCRIPTURE CD, SPARREBOOM A, FIGG WD: Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. (2005) 6(10):780-789.
   PubMed Web of Science ®Google Scholar
• NYGREN P, HANDE K, PETTY KJ et al.: Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother. Pharmacol. (2005) 55(6):609-616.
   PubMed Web of Science ®Google Scholar
• DE JONGE ME, HUITEMA AD, HOLTKAMP MJ, VAN DAM SM, BEIJNEN JH, RODENHUIS S: Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother. Pharmacol. (2005) 56(4):370-378.
   PubMed Web of Science ®Google Scholar
• IOANNIDIS JP, HESKETH PJ, LAU J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol. (2000) 18(19):3409-3422.
   PubMed Web of Science ®Google Scholar
• JANTUNEN IT, MUHONEN TT, KATAJA VV, FLANDER MK, TEERENHOVI L: 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy – a randomised study [see comments]. Eur. J. Pharmacol. (1993) 29A(12):1669-1672.
   Google Scholar
• HESKETH PJ: Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist (1999) 4(3):191-196.
   PubMedGoogle Scholar
• INOUE A, YAMADA Y, MATSUMURA Y et al.: Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support. Care Cancer (2003) 11(8):528-532.
   PubMed Web of Science ®Google Scholar
• IKEDA M, YASUI M, FUKUNAGA H et al.: Clinical usefulness of oral granisetron hydrochloride for alleviation of delayed nausea and vomiting induced by CPT-11. Eur. J. Cancer Care (Engl.) (2005) 14(5):435-439.
   PubMed Web of Science ®Google Scholar
• SCHEITHAUER W, KORNEK GV, RADERER M et al.: Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. (2003) 21(7):1307-1312.
   PubMed Web of Science ®Google Scholar
• STATHOPOULOS GP, RIGATOS SK, STATHOPOULOS JG, XYNOTROULAS JP, DIMOU E: Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am. J. Clin. Oncol. (2005) 28(6):565-569.
   PubMed Web of Science ®Google Scholar
• VASEY PA, JAYSON GC, GORDON A et al.: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. (2004) 96(22):1682-1691.
   PubMed Web of Science ®Google Scholar
• DU BOIS A, MEERPOHL HG, VACH W, KOMMOSS FGM, FENZL E, PFLEIDERER A: Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients – a study with ondansetron. Eur. J. Cancer (1992) 28:450-457.
   PubMed Web of Science ®Google Scholar
• DU BOIS A, MCKENNA CJ, ANDERSSON H et al.: A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology (1997) 54(1):7-14.
   PubMedGoogle Scholar